시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 자가면역성 용혈성 빈혈(AIHA) 치료 시장 보고서(2025년)
Autoimmune Hemolytic Anemia Treatment Global Market Report 2025
상품코드 : 1760475
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

자가면역성 용혈성 빈혈(AIHA) 치료 시장 규모는 향후 수 년간 강력한 성장이 전망될 예정입니다. 면역질환 연구에 대한 투자의 확대, 개발도상국에서의 의료 접근의 개선이라고 예측됩니다. 예측 기간 중에 예상되는 주요 동향에는 진단의 기술적 진보, 디지털 헬스와 원격 의료의 통합, 표적 치료의 진보, 진단과 약제 개발에 있어서의 AI의 이용, 새로운 면역 억제 접근의 출현 등이 포함됩니다.

자가면역 질환의 유병률 상승은 향후 수 년간 자가면역성 용혈성 빈혈(AIHA) 치료 시장의 성장을 가속할 것으로 예측됩니다. 이 증가하는 유병률은 주로 유전적 감수성에 의해 영향을 받으며, 이는 이러한 질환이 발생할 가능성을 높입니다. 자가면역성 용혈성 빈혈의 치료는 면역계의 활동으로 인한 적혈구 파괴를 최소화함으로써 이러한 질병을 관리하는 데 필수적입니다. National Institute for Health and Care Research(NIHR)는 자가면역질환은 현재 약 10명 중 1명이 병을 앓고 있으며, 19종의 자가면역질환이 인구의 약 10%-13%의 여성과 7%의 남성에 영향을 미치고 있다고 보고했습니다.

자가면역성 용혈성 빈혈(AIHA) 치료 시장의 주요 기업은 획기적인 단일클론항체와 같은 표적 치료제의 개발을 추진하고 있습니다. 이런 단일클론항체는 기존의 치료법으로는 대처할 수 없었던 독자적인 메커니즘이나 경로에 관여하는 신규 치료법입니다. Sanofi S.A는 클래식 보체계의 C1s 단백질을 억제하는 단일클론항체인 Enjaymo(스팀리맙)의 판매 승인을 유럽 위원회로부터 취득했습니다. 드문 자가면역 질환인 한랭 응집소병(CAD)의 성인에서 용혈성 빈혈을 치료하는 데 사용됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Autoimmune Hemolytic Anemia (AIHA) treatment consists of medications and therapies designed to prevent the immune system from destroying the body's own red blood cells. The primary goals of treatment are to decrease red blood cell destruction, alleviate symptoms of anemia, and avoid potential complications.

The main forms of autoimmune hemolytic anemia treatment include warm autoimmune hemolytic anemia, cold autoimmune hemolytic anemia, and other types. Warm autoimmune hemolytic anemia occurs when the immune system mistakenly attacks red blood cells at normal body temperatures, resulting in anemia. Treatment involves various classes of drugs such as corticosteroids, immunosuppressive agents, and other therapeutic options. These medications are delivered through several administration routes, including injectable, oral, and other methods. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, and online pharmacies.

The autoimmune hemolytic anemia treatment market research report is one of a series of new reports from The Business Research Company that provides autoimmune hemolytic anemia treatment market statistics, including the autoimmune hemolytic anemia treatment industry global market size, regional shares, competitors with the autoimmune hemolytic anemia treatment market share, detailed autoimmune hemolytic anemia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the autoimmune hemolytic anemia treatment industry. This autoimmune hemolytic anemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The autoimmune hemolytic anemia treatment market size has grown strongly in recent years. It will grow from $1.30 billion in 2024 to $1.41 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to greater awareness of the disease among healthcare professionals, an increasing prevalence of autoimmune disorders, expansion of hospital infrastructure, a rising number of published clinical studies, and a higher incidence of infections.

The autoimmune hemolytic anemia treatment market size is expected to see strong growth in the next few years. It will grow to $1.99 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The projected growth in the forecast period is expected to be driven by a rising global incidence of AIHA, increasing demand for targeted treatments, a growing emphasis on personalized medicine, expanding investment in autoimmune disease research, and improved healthcare access in developing countries. Key trends anticipated for the forecast period include technological progress in diagnostics, integration of digital health and telemedicine, advancements in targeted therapies, the use of AI in diagnostics and drug development, and the emergence of new immunosuppressive approaches.

The rising prevalence of autoimmune diseases is expected to drive the growth of the autoimmune hemolytic anemia treatment market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body's own tissues, resulting in inflammation and tissue damage. This growing prevalence is largely influenced by genetic susceptibility, which increases the likelihood of developing such conditions. Autoimmune hemolytic anemia treatments are vital in managing these disorders by minimizing red blood cell destruction caused by immune system activity. For example, in May 2023, the National Institute for Health and Care Research (NIHR), a UK-based organization dedicated to advancing health research, reported that autoimmune disorders now affect about one in ten individuals, with 19 different autoimmune diseases impacting approximately 10% of the population-13% of women and 7% of men. Therefore, the increasing occurrence of autoimmune diseases is driving the growth of the autoimmune hemolytic anemia treatment market.

Major companies in the autoimmune hemolytic anemia treatment market are advancing targeted therapies, such as first-in-class monoclonal antibodies, which selectively block specific immune pathways such as the classical complement system to reduce red blood cell destruction while minimizing adverse effects. These monoclonal antibodies represent novel therapies that engage unique mechanisms or pathways not previously addressed by existing treatments. For instance, in November 2022, Sanofi S.A., a healthcare company based in France, received marketing approval from the European Commission for Enjaymo (sutimlimab), a monoclonal antibody that inhibits the C1s protein in the classical complement pathway. This drug is used to treat hemolytic anemia in adults with Cold Agglutinin Disease (CAD), a rare autoimmune condition in which the immune system attacks healthy red blood cells, leading to hemolysis. Enjaymo provides a targeted approach to reducing red blood cell destruction in this form of autoimmune hemolytic anemia.

In October 2024, Recordati, a pharmaceutical company headquartered in Italy, acquired global rights to Enjaymo from Sanofi for $825 million. This acquisition is part of Recordati's strategy to strengthen its rare disease portfolio by securing a therapy for Cold Agglutinin Disease (CAD), a rare subtype of autoimmune hemolytic anemia, thereby enhancing its presence in the specialty pharmaceutical sector. Sanofi S.A. is a France-based biopharmaceutical company known for developing innovative treatments across diverse therapeutic areas.

Major players in the autoimmune hemolytic anemia treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., Hutchison China MediTech Limited, BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Kezar Life Sciences Inc.

North America was the largest region in the autoimmune hemolytic anemia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in autoimmune hemolytic anemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the autoimmune hemolytic anemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The autoimmune hemolytic anemia treatment market consists of sales of monoclonal antibodies, complement inhibitors, blood transfusions, and biosimilars. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Autoimmune Hemolytic Anemia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on autoimmune hemolytic anemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for autoimmune hemolytic anemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The autoimmune hemolytic anemia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Autoimmune Hemolytic Anemia Treatment Market Characteristics

3. Autoimmune Hemolytic Anemia Treatment Market Trends And Strategies

4. Autoimmune Hemolytic Anemia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Autoimmune Hemolytic Anemia Treatment Growth Analysis And Strategic Analysis Framework

6. Autoimmune Hemolytic Anemia Treatment Market Segmentation

7. Autoimmune Hemolytic Anemia Treatment Market Regional And Country Analysis

8. Asia-Pacific Autoimmune Hemolytic Anemia Treatment Market

9. China Autoimmune Hemolytic Anemia Treatment Market

10. India Autoimmune Hemolytic Anemia Treatment Market

11. Japan Autoimmune Hemolytic Anemia Treatment Market

12. Australia Autoimmune Hemolytic Anemia Treatment Market

13. Indonesia Autoimmune Hemolytic Anemia Treatment Market

14. South Korea Autoimmune Hemolytic Anemia Treatment Market

15. Western Europe Autoimmune Hemolytic Anemia Treatment Market

16. UK Autoimmune Hemolytic Anemia Treatment Market

17. Germany Autoimmune Hemolytic Anemia Treatment Market

18. France Autoimmune Hemolytic Anemia Treatment Market

19. Italy Autoimmune Hemolytic Anemia Treatment Market

20. Spain Autoimmune Hemolytic Anemia Treatment Market

21. Eastern Europe Autoimmune Hemolytic Anemia Treatment Market

22. Russia Autoimmune Hemolytic Anemia Treatment Market

23. North America Autoimmune Hemolytic Anemia Treatment Market

24. USA Autoimmune Hemolytic Anemia Treatment Market

25. Canada Autoimmune Hemolytic Anemia Treatment Market

26. South America Autoimmune Hemolytic Anemia Treatment Market

27. Brazil Autoimmune Hemolytic Anemia Treatment Market

28. Middle East Autoimmune Hemolytic Anemia Treatment Market

29. Africa Autoimmune Hemolytic Anemia Treatment Market

30. Autoimmune Hemolytic Anemia Treatment Market Competitive Landscape And Company Profiles

31. Autoimmune Hemolytic Anemia Treatment Market Other Major And Innovative Companies

32. Global Autoimmune Hemolytic Anemia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Autoimmune Hemolytic Anemia Treatment Market

34. Recent Developments In The Autoimmune Hemolytic Anemia Treatment Market

35. Autoimmune Hemolytic Anemia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기